Diaceutics strengthens advisory team as it prepares for greater patient impact

Diaceutics, the diagnostics data analytics, and implementation services company helping to improve patient outcomes through better testing, today announces that it is strengthening its advisory team with two thought leaders who will advise the company as it pursues its mission to transform patient diagnostic pathways.

Founded in Belfast and with offices in Dundalk and the US, Diaceutics is now a rapidly growing organisation establishing itself as a major global player in the soon to be $2 billion diagnostic commercialisation market. The company currently works with laboratory partners around the world and calls 31 of the top 35 pharmaceutical companies customers. In the 12 years since its inception, Diaceutics has helped more than half-a-million seriously ill patients access the right medication through better diagnostic testing.

As it looks to expand its patient impact, Diaceutics has retained the services of two leading external advisors. Professor Elizabeth Teisberg and Avi Kulkarni will provide strategic advice to Diaceutics founder Peter Keeling and chairwoman Julie Goonewardene as they spearhead the company’s strategic direction to remain at the forefront of precision medicine testing.

Stanford University alumnus Professor Teisberg is a thought leader in value-based health care strategy – a concept she co-created, which emphasises improving patient outcomes as a way to improve health and simultaneously reduce health care costs. Currently executive director of the Value Institute for Health and Care at the Dell Medical School in the University of Texas at Austin, she is best known for co-authoring the award-winning ‘Redefining Health Care: Creating Value-Based Competition on Results’ with Michael E. Porter.

Professor Teisberg noted: “Accurate, timely diagnosis is important to deliver appropriate and effective care. Appropriately personalised treatment protocols can achieve higher value by enabling better health outcomes for individuals at lower costs.”

Silicon Valley-based Avi Kulkarni, meanwhile, has more than 30 years of experience in the global life sciences industry and has taken an active role in the transformation of healthcare via precision medicine and articulating its future importance to the life sciences industry. Also a Stanford University graduate, Kulkarni is a Principal at KPMG, where he advises biopharma, diagnostics and medical device clients on organisational transformation, commercialisation and product life cycle strategies.

Peter Keeling, CEO, and founder, Diaceutics, said: “It is a hugely exciting time for Diaceutics as we continue to grow our business. Precision testing is rapidly moving centre stage as a key driver in therapy choice and improved patient outcomes, and we have invested in being at the forefront of that transformation.

“A key element of our investment is the retention of Elizabeth Teisberg and Avi Kulkarni. They are world-renowned specialists in their fields and we are thrilled to welcome people of their proven capability and strategic experience to consult with the organisation. These new advisors will be instrumental in helping Diaceutics chart its next steps as we continue to transform treatment pathways, driving better testing for better treatment.”